Search Results

CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government’s outbreak and preparedness response.

https://www.cslseqirus.us/news/csl-seqirus-announces-us-government-award-in-response-to-avian-influenza

CSL Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.cslseqirus.us/expertise/influenza/pandemic-response-solutions

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.cslseqirus.us/news

CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.cslseqirus.us/expertise

CSL Seqirus will deliver further H5N8 A/Astrakhan antigen to support the U.S. government's pandemic preparedness activities

https://www.cslseqirus.us/news/csl-seqirus-announces-third-us-government-award-in-relation-to-influenza-a-h5n8-candidate-vaccine

CSL Seqirus will manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. government’s pandemic preparedness activities

https://www.cslseqirus.us/news/csl-seqirus-us-government-award-to-manufacture-and-assess-influenza-a-h5n8-pre-pandemic-vaccine

Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA)

https://www.cslseqirus.us/news/seqirus-and-us-gov-renew-multi-year-agreement-for-influenza-pandemic-preparedness-and-response

CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens

https://www.cslseqirus.us/news/csl-announces-closing-of-global-collaboration-and-licensing-agreement-with-arcturus-therapeutics

CSL Seqirus confirms it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season, based on the trivalent strains recommended this week by the Vaccines and Related Biological Products Advisory Committee (VRBPAC).

https://www.cslseqirus.us/news/csl-seqirus-fully-prepared-to-implement-fdas-tiv-strain-selection-for-202425-us-season

CSL Seqirus, as a member of the CSL group, is bound by CSL's Code of Responsible Business Practice. Access our annual financial and diversity disclosures.

https://www.cslseqirus.us/our-company/corporate-responsibility/disclosures